Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 2,936 shares of Hims & Hers Health stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $26.49, for a total value of $77,774.64. Following the sale, the insider now owns 5,071 shares of the company's stock, valued at approximately $134,330.79. This represents a 36.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Irene Becklund also recently made the following trade(s):
- On Thursday, April 3rd, Irene Becklund sold 2,203 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34.
Hims & Hers Health Trading Up 5.5 %
HIMS opened at $26.75 on Thursday. The business has a 50 day moving average of $35.50 and a 200-day moving average of $30.78. The stock has a market capitalization of $5.94 billion, a price-to-earnings ratio of 60.80 and a beta of 1.65. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.
Institutional Investors Weigh In On Hims & Hers Health
A number of institutional investors have recently added to or reduced their stakes in HIMS. Perigon Wealth Management LLC raised its holdings in Hims & Hers Health by 18.1% in the 1st quarter. Perigon Wealth Management LLC now owns 16,449 shares of the company's stock valued at $486,000 after acquiring an additional 2,521 shares in the last quarter. Global Assets Advisory LLC bought a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $1,673,000. Yorktown Management & Research Co Inc acquired a new position in shares of Hims & Hers Health in the first quarter valued at $229,000. Oppenheimer & Co. Inc. lifted its position in Hims & Hers Health by 8.5% in the first quarter. Oppenheimer & Co. Inc. now owns 39,289 shares of the company's stock worth $1,161,000 after purchasing an additional 3,079 shares during the period. Finally, Crewe Advisors LLC lifted its position in Hims & Hers Health by 105.9% in the first quarter. Crewe Advisors LLC now owns 2,415 shares of the company's stock worth $71,000 after purchasing an additional 1,242 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Truist Financial cut their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $38.25.
View Our Latest Stock Analysis on HIMS
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
